Drug Metabolism of Hepatocyte-like Organoids and Their Applicability in In Vitro Toxicity Testing

Autor:	Bouwmeester, Manon C, Tao, Yu, Proença, Susana, van Steenbeek, Frank G, Samsom, Roos-Anne, Nijmeijer, Sandra M, Sinnige, Theo, van der Laan, Luc J W, Legler, Juliette, Schneeberger, Kerstin, Kramer, Nynke I, Spee, Bart, CS_STEM, Interne geneeskunde GD, CS_Genetics, IRAS OH Toxicology
Přispěvatelé:	CS_STEM, Interne geneeskunde GD, CS_Genetics, IRAS OH Toxicology, Surgery
Jazyk:	angličtina
Rok vydání:	2023
Předmět:	hepatotoxicity intrahepatic cholangiocyte organoids Organic Chemistry Pharmaceutical Science Toxicology Analytical Chemistry SDG 3 - Good Health and Well-being Chemistry (miscellaneous) Drug Discovery Molecular Medicine Physical and Theoretical Chemistry hepatic in vitro model drug-induced liver injury hepatocyte-like cells Toxicologie
Zdroj:	Molecules 28 (2023) 2 Molecules Volume 28 Issue 2 Pages: 621 Molecules, 28(2) Molecules, 28(2):621. Multidisciplinary Digital Publishing Institute (MDPI) Molecules (Basel, Switzerland), 28(2). Multidisciplinary Digital Publishing Institute (MDPI)
ISSN:	1420-3049
Popis:	Emerging advances in the field of in vitro toxicity testing attempt to meet the need for reliable human-based safety assessment in drug development. Intrahepatic cholangiocyte organoids (ICOs) are described as a donor-derived in vitro model for disease modelling and regenerative medicine. Here, we explored the potential of hepatocyte-like ICOs (HL-ICOs) in in vitro toxicity testing by exploring the expression and activity of genes involved in drug metabolism, a key determinant in drug-induced toxicity, and the exposure of HL-ICOs to well-known hepatotoxicants. The current state of drug metabolism in HL-ICOs showed levels comparable to those of PHHs and HepaRGs for CYP3A4; however, other enzymes, such as CYP2B6 and CYP2D6, were expressed at lower levels. Additionally, EC50 values were determined in HL-ICOs for acetaminophen (24.0–26.8 mM), diclofenac (475.5–>500 µM), perhexiline (9.7–>31.5 µM), troglitazone (23.1–90.8 µM), and valproic acid (>10 mM). Exposure to the hepatotoxicants showed EC50s in HL-ICOs comparable to those in PHHs and HepaRGs; however, for acetaminophen exposure, HL-ICOs were less sensitive. Further elucidation of enzyme and transporter activity in drug metabolism in HL-ICOs and exposure to a more extensive compound set are needed to accurately define the potential of HL-ICOs in in vitro toxicity testing.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ba8130e322ab28b99004e7385ce8974 http://www.scopus.com/inward/record.url?scp=85146722710&partnerID=8YFLogxK Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.